Close Menu

NEW YORK – Chugai Pharmaceutical, a subsidiary of Roche, announced today that Japan's Ministry of Health, Labour, and Welfare has granted additional approval of Foundation Medicine's FoundationOne CDx Cancer Genomic Profile as a companion diagnostic for entrectinib (Roche's Rozlytrek), marketed in Japan by Chugai.

The drug is for treating neurotrophic tyrosine receptor kinase fusion-positive solid tumors. It is a ROS1/TRK inhibitor and has been approved for treating adult and pediatric patients with NTRK fusion-positive advanced and recurrent solid tumors.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.